Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Common Equity: 2018-2024

Historic Common Equity for Whitehawk Therapeutics (WHWK) over the last 7 years, with Dec 2024 value amounting to $52.5 million.

  • Whitehawk Therapeutics' Common Equity rose 128.22% to $157.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $157.2 million, marking a year-over-year increase of 128.22%. This contributed to the annual value of $52.5 million for FY2024, which is 50.11% down from last year.
  • According to the latest figures from FY2024, Whitehawk Therapeutics' Common Equity is $52.5 million, which was down 50.11% from $105.2 million recorded in FY2023.
  • Whitehawk Therapeutics' Common Equity's 5-year high stood at $158.4 million during FY2022, with a 5-year trough of -$12.4 million in FY2020.
  • Moreover, its 3-year median value for Common Equity was $105.2 million (2023), whereas its average is $105.4 million.
  • Per our database at Business Quant, Whitehawk Therapeutics' Common Equity crashed by 134.03% in 2020 and then spiked by 1,197.22% in 2021.
  • Over the past 5 years, Whitehawk Therapeutics' Common Equity (Yearly) stood at -$12.4 million in 2020, then spiked by 1,197.22% to $136.4 million in 2021, then rose by 16.11% to $158.4 million in 2022, then plummeted by 33.58% to $105.2 million in 2023, then slumped by 50.11% to $52.5 million in 2024.